[go: up one dir, main page]

WO2002073212A3 - Analyses diagnostiques destinees a la maladie d'alzheimer - Google Patents

Analyses diagnostiques destinees a la maladie d'alzheimer Download PDF

Info

Publication number
WO2002073212A3
WO2002073212A3 PCT/GB2002/001137 GB0201137W WO02073212A3 WO 2002073212 A3 WO2002073212 A3 WO 2002073212A3 GB 0201137 W GB0201137 W GB 0201137W WO 02073212 A3 WO02073212 A3 WO 02073212A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
disease
diagnostic screens
diagnostic
screens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001137
Other languages
English (en)
Other versions
WO2002073212A2 (fr
Inventor
Zsuzsanna Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to DE60216570T priority Critical patent/DE60216570T2/de
Priority to JP2002572422A priority patent/JP4430306B2/ja
Priority to EP02704967A priority patent/EP1370870B9/fr
Priority to AU2002238766A priority patent/AU2002238766A1/en
Publication of WO2002073212A2 publication Critical patent/WO2002073212A2/fr
Publication of WO2002073212A3 publication Critical patent/WO2002073212A3/fr
Priority to US10/659,578 priority patent/US20040132113A1/en
Anticipated expiration legal-status Critical
Priority to US12/870,987 priority patent/US8377640B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des analyses diagnostiques destinées à la maladie d'Alzheimer, et notamment des tests diagnostiques fondés sur le dépistage de changements cellulaires intervenant à un stade précoce de l'évolution pathologique de la maladie d'Alzheimer.
PCT/GB2002/001137 2001-03-12 2002-03-12 Analyses diagnostiques destinees a la maladie d'alzheimer Ceased WO2002073212A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60216570T DE60216570T2 (de) 2001-03-12 2002-03-12 Verfahren zum nachweis von alzheimer-krankheit
JP2002572422A JP4430306B2 (ja) 2001-03-12 2002-03-12 アルツハイマー病の診断スクリーニング
EP02704967A EP1370870B9 (fr) 2001-03-12 2002-03-12 Analyses diagnostiques destinees a la maladie d'alzheimer
AU2002238766A AU2002238766A1 (en) 2001-03-12 2002-03-12 Diagnostic screens for alzheimer's disease
US10/659,578 US20040132113A1 (en) 2001-03-12 2003-09-10 Diagnostic screens for alzheimer's disease
US12/870,987 US8377640B2 (en) 2001-03-12 2010-08-30 Diagnostic screens for Alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106051.6A GB0106051D0 (en) 2001-03-12 2001-03-12 Diagnostic screens for alzheimer's disease
GB0106051.6 2001-12-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/659,578 Continuation US20040132113A1 (en) 2001-03-12 2003-09-10 Diagnostic screens for alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2002073212A2 WO2002073212A2 (fr) 2002-09-19
WO2002073212A3 true WO2002073212A3 (fr) 2003-05-22

Family

ID=9910482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001137 Ceased WO2002073212A2 (fr) 2001-03-12 2002-03-12 Analyses diagnostiques destinees a la maladie d'alzheimer

Country Status (9)

Country Link
US (1) US20040132113A1 (fr)
EP (2) EP1724588B1 (fr)
JP (3) JP4430306B2 (fr)
AT (1) ATE347698T1 (fr)
AU (1) AU2002238766A1 (fr)
DE (1) DE60216570T2 (fr)
ES (1) ES2272673T3 (fr)
GB (1) GB0106051D0 (fr)
WO (1) WO2002073212A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
GB0311835D0 (en) * 2003-05-22 2003-06-25 Isis Innovation Susceptibility gene for alzheimer's disease
ATE437355T1 (de) * 2006-02-03 2009-08-15 Mtm Lab Ag Verfahren zur durchführung eines denaturierungs- immunoassays
WO2010112034A2 (fr) * 2009-04-02 2010-10-07 Aarhus Universitet Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies
GB0912394D0 (en) * 2009-07-16 2009-08-26 Univ Birmingham Screening methods
GB201112246D0 (en) * 2011-07-15 2011-08-31 Univ Birmingham Diagnosis of alzheimer's disease
GB201212334D0 (en) 2012-07-11 2012-08-22 Warwick The Therapeutic targets for alzheimers disease
CN103808917B (zh) * 2014-03-16 2015-11-04 国家烟草质量监督检验中心 一种电子烟烟液细胞增殖毒性评价方法
CN103808919B (zh) * 2014-03-16 2015-11-18 国家烟草质量监督检验中心 一种基于溴脱氧尿嘧啶核苷掺入的卷烟烟气增殖毒性评价方法
WO2019113277A1 (fr) * 2017-12-08 2019-06-13 NeuroDiagnostics LLC Diagnostic d'une maladie par l'intermédiaire d'un profil d'expression génique dans des cellules synchronisées
KR102478811B1 (ko) 2020-08-21 2022-12-16 재단법인대구경북과학기술원 멀티플렉스 ｐｃｒ 플랫폼 기반의 알츠하이머 질환 진단을 위한 신규한 마커 조성물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000095A2 (fr) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Emploi d'inhibiteurs de calpaine dans l'inhibition et le traitement d'etats medicaux associes a une activite de calpaine accrue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773219A (en) * 1992-10-06 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Process for detecting Alzheimer disease using cultured cells
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP2002515740A (ja) * 1996-04-04 2002-05-28 ユニバーシティ・オブ・サウス・フロリダ プレセニリン−２遺伝子の変種
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
WO2000079000A1 (fr) * 1999-06-22 2000-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methode de detection de la maladie d'alzheimer a apparition precoce

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000095A2 (fr) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Emploi d'inhibiteurs de calpaine dans l'inhibition et le traitement d'etats medicaux associes a une activite de calpaine accrue

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JANICKI SUSAN M ET AL: "Presenilin overexpression arrests cells in the G1 phase of the cell cycle: Arrest potentiated by the Alzheimer's disease PS2(N141I) mutant.", AMERICAN JOURNAL OF PATHOLOGY, vol. 155, no. 1, July 1999 (1999-07-01), pages 135 - 144, XP002227836, ISSN: 0002-9440 *
LIU DAVID X ET AL: "Neuronal apoptosis at the G1/S cell cycle checkpoint.", CELL & TISSUE RESEARCH, vol. 305, no. 2, August 2001 (2001-08-01), pages 217 - 228, XP002227840, ISSN: 0302-766X *
NAGY Z ET AL: "CELL CYCLE KINESIS IN LYMPHOCYTES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 317, no. 2, 11 January 2002 (2002-01-11), pages 81 - 84, XP001106660, ISSN: 0304-3940 *
NAGY Z ET AL: "Cell cycle markers in the hippocampus in Alzheimer's disease.", ACTA NEUROPATHOLOGICA. GERMANY JUL 1997, vol. 94, no. 1, July 1997 (1997-07-01), pages 6 - 15, XP002227838, ISSN: 0001-6322 *
NAGY Z ET AL: "The cell division cycle and the pathophysiology of Alzheimer's disease.", NEUROSCIENCE. UNITED STATES DEC 1998, vol. 87, no. 4, December 1998 (1998-12-01), pages 731 - 739, XP002227839, ISSN: 0306-4522 *
NAGY ZS ET AL: "Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions.", ACTA NEUROPATHOLOGICA, vol. 93, no. 3, 1997, pages 294 - 300, XP002227837, ISSN: 0001-6322 *

Also Published As

Publication number Publication date
EP1724588B1 (fr) 2017-05-03
ATE347698T1 (de) 2006-12-15
GB0106051D0 (en) 2001-05-02
WO2002073212A2 (fr) 2002-09-19
JP4430306B2 (ja) 2010-03-10
US20040132113A1 (en) 2004-07-08
EP1724588A2 (fr) 2006-11-22
AU2002238766A1 (en) 2002-09-24
JP2004531244A (ja) 2004-10-14
DE60216570T2 (de) 2007-04-05
EP1724588A3 (fr) 2007-09-05
JP2010166922A (ja) 2010-08-05
EP1370870B9 (fr) 2009-12-02
EP1370870A2 (fr) 2003-12-17
JP2008245654A (ja) 2008-10-16
JP4541429B2 (ja) 2010-09-08
DE60216570D1 (de) 2007-01-18
EP1370870B1 (fr) 2006-12-06
ES2272673T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
AU2002366641A1 (en) Methods for inhibiting ocular processes
CY1111542T1 (el) Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
EP1974748A3 (fr) Anticorps pour le diagnostic d'une maladie associée à la fibrose
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
WO2005051178A3 (fr) Marqueur pour la neuromyelite optique
WO2002073212A3 (fr) Analyses diagnostiques destinees a la maladie d'alzheimer
WO2002036771A3 (fr) Imagerie, diagnostic et traitement de maladie
WO2003073211A3 (fr) Procede de realisation de tests de performances en continu
EP0848062A3 (fr) Protéase aspartique ASP1
WO2003084384A3 (fr) Diagnostic de l'infection a flavivirus
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
EP1215120A3 (fr) Cadre de séparation pour le déploiement de plusieurs satellites arrangés axialement
WO2003027251A3 (fr) Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation
WO2001085980A3 (fr) Tests enzymatiques destines au criblage d'agents anticancereux
WO2004113566A3 (fr) Reseau de proteines associees a une maladie
AU2003236714A1 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
WO2003087841A3 (fr) Proteine impliquee dans le carcinome
WO2006029838A3 (fr) Especes polypeptidiques secretees impliquees dans la maladie d'alzheimer
WO2002059619A3 (fr) Methode permettant de diagnostiquer la maladie d'alzheimer et d'autres troubles associes au prion de cette maladie
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
WO2002061079A3 (fr) Biligands
WO2003014389A3 (fr) Methode
AU2001273675A1 (en) Methods and assays for diagnosing alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10659578

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002572422

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002704967

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002704967

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002704967

Country of ref document: EP